What is ScreenIn3D?
ScreenIn3D is at the forefront of biotechnology innovation, specializing in the development of advanced lab-on-a-chip technologies. These sophisticated platforms are designed to revolutionize cancer drug discovery, offering a more efficient and precise method for identifying and testing potential therapeutic agents. The company's focus on this critical area of medical research positions it as a key player in the biotech landscape, aiming to accelerate the development of life-saving treatments.
How much funding has ScreenIn3D raised?
ScreenIn3D has raised a total of $1M across 1 funding round:
Seed
$1M
Seed (2025): $1M with participation from University of Strathclyde Glasgow, The TRICAPITAL Syndicate, Gabriel Investments, and Nidobirds Ventures
Key Investors in ScreenIn3D
University of Strathclyde Glasgow
A leading international technological university based in Glasgow, recognized for its excellence in energy innovation and advanced manufacturing, integrating academics, research, and industry engagement.
The TRICAPITAL Syndicate
A business angel syndicate based in the Scottish Borders, focused on investing in and supporting growth businesses with extensive experience in enterprise development.
Gabriel Investments
An investment group dedicated to supporting high-potential early-stage technology companies, particularly those in the Philadelphia region, offering financial backing and operational expertise.
What's next for ScreenIn3D?
With this substantial enterprise-level funding, ScreenIn3D is poised for significant expansion and accelerated research and development. The strategic investment will likely fuel the scaling of its operations, further refinement of its proprietary lab-on-a-chip technology, and the expansion of its drug discovery pipeline. This backing signals strong confidence in ScreenIn3D's potential to make a substantial impact on cancer research and treatment, paving the way for future growth and market leadership in the biotechnology sector.
See full ScreenIn3D company page
